Zacks Analyst Blog Highlights: Cisco Systems, Apple, Google, Merge Healthcare and Allscripts Healthcare - Press Releases

For Immediate Release

Chicago, IL – November 11, 2010 – Zacks.com Analyst Blog features: Cisco Systems (CSCO), Apple, Inc. (AAPL), Google, Inc. (GOOG), Merge Healthcare (MRGE) and Allscripts Healthcare (MDRX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday's Analyst Blog:

Cisco Slips on Earnings, Revs

Networking gear giant Cisco Systems (CSCO) reported fiscal 1st quarter 2011 earnings after the bell Wednesday, missing the Zacks Consensus Estimates slightly on both the top and bottom lines. Cisco brought in $10.75 billion in revenues in the quarter, below the $10.76 billion expected, and the company reported earnings of 34 cents per share (GAAP), short of the consensus by a penny.

Investors and analysts alike had been cautiously optimistic ahead of the earnings announcement from the global leader in router and switcher production. Cisco shares had been up nearly 1% in the week to date prior to the announcement, and 2 of 14 analysts had upwardly revised quarterly estimates in the past month. Shares have tumbled 4% (roughly $1 per share) in the after-market.

This was the first earnings miss in at least the past 5 quarters. During fiscal 2010, Cisco beat expectations by an average of 11.6% per quarter. The short-term rating before the report was a Zacks #3 Rank (Hold), while the longer-term outlook was an Outperform recommendation on Cisco shares.

In order to compete with other tech giants like Apple, Inc. (AAPL) and Google, Inc. (GOOG) which have branched out into finished consumer products businesses, Cisco bought out two private firms in the 1st quarter, ExtendMedia and Arch Rock. But Cisco also bought back 113 million shares for $2.5 billion in the quarter. And with the after-market sell-off, CSCO shares are now showing a loss year-to-date.

The earnings call should hopefully answer most questions this slightly disappointing report raises. Thursday morning, before the bell, we will publish an in-depth take on Cisco's numbers, as well as the company's outlook.

Strong Quarter for Merge

Merge Healthcare (MRGE) reported net loss per share of 6 cents in the third quarter of fiscal 2010 compared with loss of 2 cents in the year-ago period. However, after adjusting for certain items, the company reported an EPS of 4 cents, surpassing both the Zacks Consensus Estimate and the prior-year quarter by 3 cents.

Merge reported revenues of $45.2 million, up 167.5% from $16.9 million in the year-ago period. Results for the reported quarter include sales of AMICAS, which was acquired in April 2010. However, adjusted revenue was $48.5 million, higher than the year-ago quarter's adjusted revenue of $45.7 million and the Zacks Consensus Estimate of $43 million. The company derives revenues from three sources – software and others, professional services, and maintenance and EDI - which recorded an annualized growth of 66.7% to $12.9 million, 77.1% to $6.8 million and 380% to $25.4 million, respectively. Recurring revenues were greater than 65% of net sales during the quarter, unchanged from the year-ago quarter.

Merge also made some changes to its top management. The company announced its new CEO, Jeffrey Surges, who was the president of sales at Allscripts Healthcare (MDRX), a Merge partner. Surges' predecessor, Justin Dearborn, will now focus on the company's international business.

The overall US health IT (HIT) market witnessed a dramatic change in February 2009 with the passing of the Health Information Technology for Economic and Clinical Health (HITECH) Act, as part of the American Recovery and Reinvestment Act (ARRA), an economic stimulus bill. According to the HITECH Act, almost $20 billion will be spent on health care providers who can demonstrate by 2011 that they are using HIT applications in meaningful ways to reduce the overall healthcare costs. The incentives will be offered for a period of 4-5 years after which physicians will be penalized for not adopting proper measures.

We are encouraged to note that Merge has witnessed an improvement in the overall industry trends. Though initially confusing, the requirements to qualify for the funds are now becoming clearer, helping health providers make the necessary purchases.

Merge has made several acquisitions over the past few years, the latest being the acquisition of AMICAS Inc. for approximately $248 million, which will benefit the company in the long term. While Merge is primarily focused on outpatient imaging sites in the radiology information system, picture archiving and communication systems (RIS/PACS market), AMICAS earns revenues from outpatient imaging sites as well as radiology, cardiology, and enterprise solutions in the hospital market.

Outlook

For 2011, Merge expects to record $235-$240 million of adjusted revenue, well above the Zacks Consensus Estimate of $205 million.

Recommendation

There is immense potential in the diagnostic imaging market, especially with the government's emphasis on HIT and an ageing population. The acquisition of AMICAS has transformed Merge into a stronger company, with an expanded product portfolio. However, the presence of many big players has made the diagnostic imaging market highly competitive.

For the long term, we have a Neutral rating on Merge Healthcare. The stock retains a Zacks #3 Rank (Hold) for the short term.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com